Estudio prospectivo multicéntrico de experiencia en práctica clínica real en el control de medidas de desenlace reportadas por el paciente (PRO) diagnosticado de artritis psoriásica y/o espondiloartritis y que inicia tratamiento con secukinumab

[1]  H. Mann,et al.  Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study , 2019, Rheumatology and Therapy.

[2]  D. Cella,et al.  General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  D. Veale,et al.  The pathogenesis of psoriatic arthritis , 2018, The Lancet.

[4]  T. Luger,et al.  Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  K. Pavelka,et al.  Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 , 2017, Arthritis Research & Therapy.

[6]  J. Koo,et al.  Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature. , 2017, Skin therapy letter.

[7]  J. Szepietowski,et al.  Secukinumab in the treatment of psoriasis: an update. , 2017, Immunotherapy.

[8]  V. Strand,et al.  Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) , 2016, Annals of the rheumatic diseases.

[9]  D. Gladman,et al.  Psoriatic Arthritis. , 2017, The New England journal of medicine.

[10]  A. Blauvelt.  Safety of secukinumab in the treatment of psoriasis , 2016, Expert opinion on drug safety.

[11]  D. Gladman,et al.  The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study , 2016, Arthritis & rheumatology.

[12]  M. Dougados,et al.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.

[13]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[14]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[15]  G. Yancopoulos,et al.  Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) , 2014, Annals of the rheumatic diseases.

[16]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[17]  M. Dougados,et al.  Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials , 2013, Annals of the rheumatic diseases.

[18]  J. Paramarta.  Spondyloarthritis: From disease phenotypes to novel treatments , 2014 .

[19]  C. Morin,et al.  Validation of the Insomnia Severity Index in Primary Care , 2013, The Journal of the American Board of Family Medicine.

[20]  E. Brouwer,et al.  Validity and Reliability of the Dutch Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire , 2013, PloS one.

[21]  Patrick Durez,et al.  Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study , 2012, Annals of the rheumatic diseases.

[22]  J. Braun,et al.  [Ankylosing spondylitis. Target treatment criteria]. , 2009, Zeitschrift fur Rheumatologie.

[23]  J. Braun,et al.  Spondylitis ankylosans , 2009, Zeitschrift für Rheumatologie.

[24]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[25]  D. Gladman,et al.  Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis , 2007, Annals of the rheumatic diseases.

[26]  J. Listing,et al.  Open label trial of anakinra in active ankylosing spondylitis over 24 weeks , 2004, Annals of the rheumatic diseases.

[27]  A. Tennant,et al.  Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis , 2004, Annals of the rheumatic diseases.

[28]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[29]  T. Pincus,et al.  Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. , 2002, The Journal of rheumatology.

[30]  S. Berra,et al.  El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria , 2001 .

[31]  X. Carné,et al.  La evaluación de la calidad de vida en el contexto del ensayo clínico , 1998 .